Development of novel pain relief agents acting through the selective activation of the delta-opioid receptor
by
Dondio G SmithKline Beecham S.p.A.,
Department of Medicinal Chemistry,
Milan, Italy.
massimo_dondio@sbpharm.com
Farmaco 2000 Mar; 55(3):178-80

ABSTRACT

A continuing effort in the development of non-peptide delta-opioid agonists as possible safe and effective pain relief agents has been seen in the last years. Novel potent and selective delta-opioid agonists based on the pirrolomorphinan framework have been designed, synthesised and biologically characterised in our laboratories. In particular, compound 7 (SB 235863) proved the concept that a selective delta-opioid agonist may be a valuable pain relief agent free of the unwanted side-effects usually associated with narcotic analgesics such as morphine.

Delta agonists
Learned helplessness
Enkephalinase inhibitors : RB801
Delta opioid receptors and anxiety
Delta agonists/Parkinson's therapy
Opioids, brain stimulation and reward
Cholecystokinin and delta opioid receptors
Delta-opioid receptor agonists as antidepressants?
Co-existence of dopamine-D1 and delta-opioid receptors

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family